Tonix Pharmaceuticals : Factsheet

NASDAQ: TNXP

HQ: Chatham, NJ

investor.relations@

tonixpharma.com

MANAGEMENT TEAM

Seth Lederman, MD

Co-Founder, CEO & Chairman

Gregory Sullivan, MD

Chief Medical Officer

Bradley Saenger, CPA

Chief Financial Officer

Jessica Morris

Chief Operating Officer

MAIN U.S. OFFICES

New Jersey Office

(Corporate & Tonix

Medicines Headquarters)

26 Main Street - Ste 101

What We Do

Tonix is a biopharmaceutical company that commercializes, develops, discovers and licenses therapeutics to treat and prevent human disease and alleviate suffering. Tonix is focused on filing the NDA for TNX-102

SL (sublingual cyclobenzaprine) with the FDA for the management of fibromyalgia in the 2nd half of 2024. The NDA is supported by two positive Phase 3 trials

Leveraging the expertise of the Company's leaders, Tonix's strategy includes:

• Progressing our curated portfolio of product candidates in development, including small molecule drugs and biologics, with a focus on central nervous system disorders
• Marketing FDA-approved products through our expanding in-housecapabilities and expertise in the migraine and pain space
• Partnering strategically with government institutions, other biotech companies and world-class academic organizations to reduce internal spend and bring innovative therapeutics to market faster

Key Clinical Candidates

	TNX-102 SL is a non-opioid,non-addictive
TNX-102 SL	treatment in development for the
management of fibromyalgia (FM) and other
Fibromyalgia
CNS indications such as FM-type Long
	COVID and Acute Stress Disorder (ASD)

Chatham, NJ 07928

Research and Development Center (RDC)

431 Aviation Way Frederick, MD 21701

Advanced Development Center (ADC)

259 Samuel Barnet Blvd

New Bedford Business Park

North Dartmouth, MA 02745

www.tonixpharma.com

@TonixPharma

TNX-1300

Cocaine

Intoxication

TNX-2900

Prader-Willi

Syndrome

TNX-1500

Transplant

Rejection

TNX-1300 is a recombinant protein which rapidly degrades cocaine in the bloodstream and has received FDA Breakthrough Therapy Designation as well as a Cooperative Agreement Grant from the National Institute on Drug Abuse (NIDA)

TNX-2900 is a novel formulation of intranasal oxytocin potentiated with magnesium in development for the treatment of Prader-Willi Syndrome, a rare genetic disorder, and has received FDA Orphan Drug Designation

TNX-1500 is a next generation anti-CD40L mAb designed to preserve efficacy without risk of thrombosis in development for the prevention of organ transplant rejection and autoimmune conditions

Version P0563 April 30, 2024 (Doc 1430)

Development Pipeline: Key Product Candidates

Using our integrated development engine, we advance innovative programs toward FDA approval

Molecule*	Indication	Phase 1	Phase 2	Phase 3	NDA
Submission
	Fibromyalgia	Statistically Significant Phase 3 Topline Results	Expected 2H'24
		Reported 4Q'23

TNX-102 SL		Phase 2 Topline Results
	Long COVID
Cyclobenzaprine HCl	Reported 3Q'23
Protectic® Sublingual Tablets
	Acute Stress Disorder	Phase 2 Study** Start
	Expected 2Q'24
TNX-1300
Cocaine Esterase	Cocaine Intoxication	Phase 2 Study Start
Expected 2Q'24
NIDA Funded & Breakthrough
Therapy Designation
TNX-2900
Intranasal Potentiated Oxytocin	Prader-Willi Syndrome	Phase 2 Ready
FDA Orphan Drug and Rare
Pediatric Disease Designation
TNX-1500	Organ Transplant	Phase 1	Clinical Stage Complete
Anti-CD40L mAb	Rejection/ Autoimmune	Study
Conditions	Ongoing

*All of Tonix's product candidates are investigational new drugs or biologics and have not been approved for any indication. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. **Investigator-Initiated study

Filing NDA for the management of fibromyalgia supported by two positive Phase 3 trials expected 2H'24

Two CNS programs (Cocaine Intoxication and ASD) expected to begin enrolling in Phase 2 trials in 1H'24

TNX-1500 Phase 1 study clinical phase complete

Our Commercial Strategy

We market two FDA-approved products for the treatment of acute migraine

	Zembrace® SymTouch®	Tosymra®
Indication	Acute migraine with or without aura in adults	Acute migraine with or without aura in adults
Delivery	Sumatriptan injection, 3 mg	Sumatriptan nasal spray, 10 mg
	Only branded sumatriptan autoinjector promoted in the	Formulated with a permeation enhancer (Intravail®
	technology) that provides rapid and efficient absorption
Design	U.S.
of sumatriptan
Designed for ease of use and favorable tolerability with
	Pharmacokinetically equivalent to 4 mg subcutaneous
	low 3 mg dose
	sumatriptan
Patent	Patent protection until 2036	Patent protection until 2031
Protection

© 2024 Tonix Pharmaceuticals Holding Corp.

All rights reserved.